SLGT-2抑制剂在糖尿病脂肪肝患者的治疗中对血清瘦素水平的作用观察  

Effect observation of SLGT-2 inhibitor on serum leptin level in patients with diabetic fatty liver disease

作　　者：王丽娜 周林 Wang Lina;Zhou Lin

机构地区：[1]青岛市城阳人民医院

出　　处：《中医临床研究》2019年第30期49-50,共2页Clinical Journal Of Chinese Medicine

摘　　要：目的:探讨SLGT-2抑制剂在糖尿病脂肪肝患者的治疗中对血清瘦素水平的作用观察。方法:将2017年5月-2018年5月在我院内分泌科治疗的100例糖尿病脂肪肝患者随机分为两组,对照组常规使用控制饮食、加强运动、口服二甲双胍治疗,观察组在此基础上使用达格列净治疗,比较两组患者的临床疗效、血脂各指标变化、胰岛素抵抗及血清瘦素水平。结果:观察组治疗总有效率为96%,明显高于对照组的78%(P <0.05);观察组治疗后TC、TG、HDL-C、LDL-C、BMI水平与对照组相比明显改善(P <0.05);观察组治疗后HOMA-IR、血清瘦素水平明显低于对照组,而HOMA-IS明显高于对照组(P<0.05)。结论:SLGT-2抑制剂在糖尿病脂肪肝患者的治疗中效果显著,能有效降低血脂及体重,改善胰岛素抵抗,降低血清瘦素,促进病情的缓解,具有积极的临床意义。Objective: To explore the effect of SLGT-2 inhibitor on serum leptin level in patients with diabetic fatty liver disease. Methods: 100 cases of diabetic fatty liver patients treated in endocrinology department of our hospital from May 2017 to May 2018 were randomly divided into two groups. Results: The effective rate was 96% in the observation group, which was significantly higher than 78% in the control group(P<0.05). TC, TG, HDL-C and BMI of the observation group were significantly improved after treatment compared with the control group(P<0.05). After treatment, HOMA-IR and serum leptin levels in the observation group were significantly lower than those in the control group, while HOMA-IS levels were significantly higher than those in the control group(P < 0.05). Conclusion: SLGT-2 inhibitor has a significant effect in the treatment of patients with diabetic fatty liver, which can effectively reduce blood lipid and body weight, improve insulin resistance, reduce serum leptin, and promote the remission of the disease, which is with positive clinical significance.

关 键 词：糖尿病 脂肪肝 SLGT-2抑制剂 达格列净 血清瘦素 胰岛素抵抗 

分 类 号：R587.2[医药卫生—内分泌]